Calcitonin (Salmon): Evidence, Mechanism & Legal Status

Calcitonin (salmon) is a 32-amino-acid peptide hormone — secreted physiologically by thyroid parafollicular (C) cells — that directly inhibits osteoclastic bone resorption and acutely lowers serum calcium.1 Unlike the experimental tissue-repair peptides that dominate consumer interest, calcitonin is a legacy approved drug, first cleared by the FDA in 1975. The question is not whether it works, but how much, for whom, and at what risk. This monograph separates the established human evidence from the hype.

This article is informational and editorial content for research and educational purposes only. It is not medical advice, not a protocol to follow, and not a sourcing guide. Calcitonin salmon is a prescription-only hormone with a label malignancy warning and anaphylaxis risk. Dosing figures are reported strictly as published in FDA labeling and the clinical literature, for completeness — not as recommendations. Consult a licensed clinician before any health decision.

What is calcitonin and how does it work?

Calcitonin is a single-chain, 32-amino-acid polypeptide with an N-terminal 1–7 disulfide ring and a C-terminal prolinamide. The salmon analog, derived from the fish ultimobranchial gland, differs from human calcitonin across roughly amino acids 10–27, conferring higher receptor affinity, slower metabolic clearance and greater resistance to degradation — which is why it, not native human calcitonin, is the therapeutic standard.19 Commercial products are synthetic or recombinant in origin.

The mechanism — and this part is itself Grade A — centers on the calcitonin receptor (CTR), a class-B G-protein-coupled receptor expressed prominently on osteoclasts and in kidney and CNS. Receptor engagement couples to Gαs, activating adenylate cyclase and the cAMP/PKA pathway, plus a parallel phospholipase-C/IP3 pathway.1 Within minutes, osteoclasts contract, lose the ruffled border required for resorption, retract and reduce motility; calcitonin also inhibits osteoclast carbonic anhydrase II — disrupting the acidic resorption microenvironment — and blocks osteoclast-precursor differentiation. The net effect is a rapid, reversible shutdown of bone resorption.1 In the kidney it reduces tubular reabsorption of calcium and phosphate and promotes diuresis, adding to its acute calcium-lowering.1

Two limitations are built into the pharmacology. First, because CTR is essentially absent from osteoblasts and bone formation is coupled to resorption, any pro-formation effect is indirect; preclinical signals such as osteoclast Wnt10b induction in ovariectomized rats remain Grade C, animal-only.10 Second, osteoclasts partially escape calcitonin's effect within about 24 to 48 hours via receptor downregulation, capping sustained antiresorptive potency and explaining why the calcium-lowering effect in hypercalcemia fades after one to two days.1 Pharmacokinetically, absolute bioavailability is about 71% subcutaneous and 66% intramuscular, with intranasal bioavailability low (~3% absolute); the terminal half-life is roughly 58 to 64 minutes.2

What is the evidence by indication?

Calcitonin's evidence is human-grade across several indications, but the effect sizes shrink as you move from acute calcium control toward chronic osteoporosis. The FDA's own meta-analytic and trial record (summarized in the prescribing information and in the StatPearls review) anchors the picture; readers can inspect the underlying registry record at the StatPearls calcitonin monograph.1

Hypercalcemia is calcitonin's most defensible modern role. Onset is roughly two hours; it lowers serum calcium about 1 to 2 mg/dL within four to six hours, but the effect attenuates after 24 to 48 hours due to osteoclast escape — so it functions as a bridge alongside saline rehydration while a slower, durable bisphosphonate takes effect.13 In Paget's disease it reduces bone pain and biochemical turnover — one classic series (n=85) reported roughly 50% reductions in alkaline phosphatase and urinary hydroxyproline over three to six months — but it has been displaced by single-infusion zoledronic acid, and long-term efficacy is undercut by neutralizing anti-calcitonin antibodies that develop in roughly half of treated patients.12

Osteoporosis is where the limits are clearest. The pivotal PROOF RCT (Prevent Recurrence Of Osteoporotic Fractures; n≈1,255, with about 59% dropout) found 200 IU/day intranasal reduced new vertebral fractures by roughly 33 to 36% versus placebo, but with only modest lumbar BMD gains (~1 to 1.5%), no hip or non-vertebral fracture benefit, and a paradoxical lack of dose-dependence (200 IU beat 400 IU).3 A large oral-calcitonin RCT (0.8 mg/day over 36 months, n=4,665) showed no significant vertebral or non-vertebral fracture reduction (p=0.94).3 Head-to-head, alendronate produced significantly greater BMD gains and turnover suppression, and FDA labeling now states fracture-reduction efficacy is not demonstrated for the injectable.2 A separate meta-analysis of intranasal calcitonin reinforces a real but small osteoporosis effect.11 For acute osteoporotic vertebral-fracture pain, several small RCTs support short-term analgesia, framing calcitonin as a bridge until the pain resolves.3

What doses appear in the literature?

Reported strictly as information from FDA labeling and the clinical literature, not as a protocol.2 For acute hypercalcemia: 4 IU/kg SC/IM every 12 hours, escalating to 8 IU/kg every 12 then every 6 hours if response is inadequate over successive one-to-two-day intervals, used with hydration and often a bisphosphonate.2 For Paget's disease: 100 IU/day SC/IM initially, with maintenance around 50 IU/day or 50 to 100 IU every one to three days.2 For postmenopausal osteoporosis: 200 IU/day intranasal (one spray, alternating nostrils) or 100 IU/day SC/IM, with at least 1,000 mg elemental calcium and 400 IU vitamin D daily.2 Subcutaneous injection is preferred for volumes under 2 mL and intramuscular for larger; the nasal spray is stored refrigerated, brought to room temperature, and primed before first use, and skin testing is advised before parenteral use in patients with suspected hypersensitivity.21

How safe is calcitonin?

Common adverse events differ by route. Parenteral use brings nausea (~10%, often transient), facial and hand flushing within minutes, injection-site inflammation, diarrhea and increased urinary frequency; intranasal use causes rhinitis, epistaxis, nasal crusting and dryness, and nasal mucosal ulceration (discontinue if ulceration exceeds 1.5 mm), with adverse events rising with age.1 Because it is a foreign, fish-derived peptide, calcitonin salmon can cause urticaria, bronchospasm, tongue or throat swelling and fatal anaphylaxis, so skin testing is recommended for suspected hypersensitivity with epinephrine available.2 Excess effect can cause symptomatic hypocalcemia, and pre-existing hypocalcemia must be corrected before initiation.2

The central safety concern is a malignancy signal. A pooled FDA meta-analysis of 21 RCTs found higher overall malignancy incidence — 4.1% (254/6,151) in calcitonin patients versus 2.9% (137/4,732) placebo, a risk difference of about 1.0% (95% CI 0.3 to 1.6) — driven by basal cell carcinoma and a separate prostate-cancer signal in oral-calcitonin trials; the label states it is 'not possible to exclude an increased risk.'2 An independent review and meta-analysis concluded the association is weak, with causality unlikely and no established mechanism, though the signal is described as consistent.45 Long-term response is also blunted by neutralizing antibodies and osteoclast escape, and lithium levels may fall via increased renal clearance.2

What is the FDA, EMA and WADA status in 2026?

Salmon calcitonin has been FDA-approved since 1975; both intranasal and injectable formulations carry approval for Paget's, hypercalcemia, and a restricted postmenopausal-osteoporosis indication. It is a legitimate, prescription-only approved drug.2 A 2023 Federal Register determination confirmed that injectable Miacalcin 100 USP Units/mL was not withdrawn for safety or effectiveness — it sits on the discontinued-marketing list for commercial reasons, and ANDAs referencing it may still be approved.6

Abroad, the indication has been pared back. The EMA advised in July 2012 that salmon calcitonin no longer be used for postmenopausal osteoporosis, citing malignancy risk plus weak benefit; a 2013 FDA joint advisory committee voted 12–9 that the benefit–risk did not support nasal calcitonin for osteoporosis; Health Canada withdrew nasal calcitonin in October 2013 and Taiwan followed in December 2013.37 The U.S. FDA did not withdraw it but added the malignancy warning and restricted osteoporosis use to alternatives-failed cases. For athletes, calcitonin salmon is not named on the 2026 WADA Prohibited List, though a product that lost all regulatory approval could theoretically fall under WADA's catch-all S0 — so athletes should verify the specific product on GlobalDRO.8 It is not a controlled substance.

Bottom line. Calcitonin salmon is a real, FDA-approved bone hormone with Grade A human evidence — but for modest effects in a shrinking niche. Its mechanism is well established and rapid, making it most defensible for acute hypercalcemia (a 24-to-48-hour bridge) and short-term analgesia of acute osteoporotic vertebral fracture. For osteoporosis it is last-line: the PROOF trial showed only ~36% vertebral-fracture reduction with no hip benefit, oral calcitonin failed, and bisphosphonates, denosumab and anabolics are clearly superior. The malignancy signal is real on paper but weak and mechanism-less. Calcitonin is a legacy agent to know, not a frontier one to chase. Regulatory facts here are current as of June 2026 and should be re-verified against FDA, EMA and WADA/GlobalDRO before relying on them.